Current Status of Hepatitis E Virus Seroprevalance, İstanbul, Türkiye

Mehmet Karabey; Sema Alaçam; Nuran Karabulut

Article Details

Current Status of Hepatitis E Virus Seroprevalance, İstanbul, Türkiye

Authors:

Mehmet Karabey | Sema Alaçam | Nuran Karabulut

Publisher:

Bolu Abant Izzet Baysal University

Main Topics:

Virology

Journal:

Abant Medical Journal Vol.14 Issue 2, pp.73-78

Document Type:

Article

Publication Date:

8/2025

Document Language:

English

Document ID (Org No.):

2001356688

pISSN:

1305-4392

Keywords:

Abstract:

 Background Hepatitis E virus HEV infection is one of the most common causes of acute viral hepatitis, and it is estimated to lead to approximately 44,000 deaths annually from 20 million HEV infections worldwide. This study aims to examine the seroprevalence of hepatitis E in our region and to provide an updated contribution to the limited hepatitis E seroprevalence data available in our country. Methods Cases tested for Anti-HEV IgM and Anti-HEV IgG antibodies between January 2021 and October 2023 were analyzed. Hepatitis E-specific IgM and IgG antibodies were analyzed using the EUROIMMUN Anti-HEV IgM and IgGEUROIMMUN AG, Germany commercial kits with the Triturus GRIFOLS,Spain device. Results The study included 65 patients who were tested for HEV-IgM and HEV-IgG, with a mean age of 29.5519.56years. Of the 65 patients, 37 were female, 21 were children, and 2 were of foreign nationality. No reactivity was detected in the HEV-IgM tests conducted on the 65 patients. HEV-IgG reactivity was detected in 4 patients, with a seropositivity rate of 6. All of the HEV seropositive cases were adults, including three males and one female. The HEV seroprevalence was higher in males10.7 compared to females2.7, with a statistically significant difference between the two groupsp0.001. Conclusion The hepatitis E seroprevalence in our region was found to be 6, which is below the national average in Turkey, and no active HEV infection was detected. Determining seroprevalence is valuable for preventing outbreaks, developing protective policies such as sanitation and hygiene, and especially for establishing accurate vaccination programs.

 Background Hepatitis E virus HEV infection is one of the most common causes of acute viral hepatitis, and it is estimated to lead to approximately 44,000 deaths annually from 20 million HEV infections worldwide. This study aims to examine the seroprevalence of hepatitis E in our region and to provide an updated contribution to the limited hepatitis E seroprevalence data available in our country. Methods Cases tested for Anti-HEV IgM and Anti-HEV IgG antibodies between January 2021 and October 2023 were analyzed. Hepatitis E-specific IgM and IgG antibodies were analyzed using the EUROIMMUN Anti-HEV IgM and IgGEUROIMMUN AG, Germany commercial kits with the Triturus GRIFOLS,Spain device. Results The study included 65 patients who were tested for HEV-IgM and HEV-IgG, with a mean age of 29.5519.56years. Of the 65 patients, 37 were female, 21 were children, and 2 were of foreign nationality. No reactivity was detected in the HEV-IgM tests conducted on the 65 patients. HEV-IgG reactivity was detected in 4 patients, with a seropositivity rate of 6. All of the HEV seropositive cases were adults, including three males and one female. The HEV seroprevalence was higher in males10.7 compared to females2.7, with a statistically significant difference between the two groupsp0.001. Conclusion The hepatitis E seroprevalence in our region was found to be 6, which is below the national average in Turkey, and no active HEV infection was detected. Determining seroprevalence is valuable for preventing outbreaks, developing protective policies such as sanitation and hygiene, and especially for establishing accurate vaccination programs.

 Background Hepatitis E virus HEV infection is one of the most common causes of acute viral hepatitis, and it is estimated to lead to approximately 44,000 deaths annually from 20 million HEV infections worldwide. This study aims to examine the seroprevalence of hepatitis E in our region and to provide an updated contribution to the limited hepatitis E seroprevalence data available in our country. Methods Cases tested for Anti-HEV IgM and Anti-HEV IgG antibodies between January 2021 and October 2023 were analyzed. Hepatitis E-specific IgM and IgG antibodies were analyzed using the EUROIMMUN Anti-HEV IgM and IgGEUROIMMUN AG, Germany commercial kits with the Triturus GRIFOLS,Spain device. Results The study included 65 patients who were tested for HEV-IgM and HEV-IgG, with a mean age of 29.5519.56years. Of the 65 patients, 37 were female, 21 were children, and 2 were of foreign nationality. No reactivity was detected in the HEV-IgM tests conducted on the 65 patients. HEV-IgG reactivity was detected in 4 patients, with a seropositivity rate of 6. All of the HEV seropositive cases were adults, including three males and one female. The HEV seroprevalence was higher in males10.7 compared to females2.7, with a statistically significant difference between the two groupsp0.001. Conclusion The hepatitis E seroprevalence in our region was found to be 6, which is below the national average in Turkey, and no active HEV infection was detected. Determining seroprevalence is valuable for preventing outbreaks, developing protective policies such as sanitation and hygiene, and especially for establishing accurate vaccination programs.

 Background Hepatitis E virus HEV infection is one of the most common causes of acute viral hepatitis, and it is estimated to lead to approximately 44,000 deaths annually from 20 million HEV infections worldwide. This study aims to examine the seroprevalence of hepatitis E in our region and to provide an updated contribution to the limited hepatitis E seroprevalence data available in our country. Methods Cases tested for Anti-HEV IgM and Anti-HEV IgG antibodies between January 2021 and October 2023 were analyzed. Hepatitis E-specific IgM and IgG antibodies were analyzed using the EUROIMMUN Anti-HEV IgM and IgGEUROIMMUN AG, Germany commercial kits with the Triturus GRIFOLS,Spain device. Results The study included 65 patients who were tested for HEV-IgM and HEV-IgG, with a mean age of 29.5519.56years. Of the 65 patients, 37 were female, 21 were children, and 2 were of foreign nationality. No reactivity was detected in the HEV-IgM tests conducted on the 65 patients. HEV-IgG reactivity was detected in 4 patients, with a seropositivity rate of 6. All of the HEV seropositive cases were adults, including three males and one female. The HEV seroprevalence was higher in males10.7 compared to females2.7, with a statistically significant difference between the two groupsp0.001. Conclusion The hepatitis E seroprevalence in our region was found to be 6, which is below the national average in Turkey, and no active HEV infection was detected. Determining seroprevalence is valuable for preventing outbreaks, developing protective policies such as sanitation and hygiene, and especially for establishing accurate vaccination programs.

Article Details

Current Status of Hepatitis E Virus Seroprevalance, İstanbul, Türkiye

Authors:

Mehmet Karabey | Sema Alaçam | Nuran Karabulut

Publisher:

Bolu Abant Izzet Baysal University

Main Topics:

Virology

Journal:

Abant Medical Journal Vol.14 Issue 2, pp.73-78

Document Type:

Article

Publication Date:

8/2025

Document Language:

English

Document ID (Org No.):

2001356688

pISSN:

1305-4392

Hepatitis E virus

hepatitis E vaccine

seroprevalence

Istanbul

Issues

Article Details

Current Status of Hepatitis E Virus Seroprevalance, İstanbul, Türkiye

Authors: Mehmet Karabey | Sema Alaçam | Nuran Karabulut

Publisher: Bolu Abant Izzet Baysal University

Main Topics: Virology

Journal: Abant Medical Journal Vol.14 Issue 2, pp.73-78

Document Type: Article

Publication Date: 8/2025

Document Language: English

Document ID (Org No.): 2001356688

pISSN: 1305-4392

Hepatitis E virus

hepatitis E vaccine

seroprevalence

Istanbul

Issues

Authors:

Mehmet Karabey | Sema Alaçam | Nuran Karabulut

Publisher:

Bolu Abant Izzet Baysal University

Main Topics:

Virology

Journal:

Abant Medical Journal Vol.14 Issue 2, pp.73-78

Document Type:

Article

Publication Date:

8/2025

Document Language:

English

Document ID (Org No.):

2001356688

pISSN:

1305-4392